European Union - English - myHealthbox

finox biotech ag - follitropin alfa - solution for injection in pre-filled pen (injection). - 75 iu/0.125ml - anovulation - sex hormones and modulators of the genital systems - in adult women - anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate. - stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift). - follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l. in adult men - follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

European Union - English - EMA (European Medicines Agency)

theramex ireland limited - follitropin alfa - anovulation - sex hormones and modulators of the genital system, - in adult womenanovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate;stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer and zygote intra-fallopian transfer;ovaleap in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l.in adult menovaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hcg) therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - follitropin alfa 150 [iu] (rch, + 10% overage);  ; lutropin alfa, rch 75 [iu] (+ 23% overage) - powder for injection - 150 iu/75 iu - active: follitropin alfa 150 [iu] (rch, + 10% overage)   lutropin alfa, rch 75 [iu] (+ 23% overage) excipient: dibasic sodium phosphate dihydrate methionine monobasic sodium phosphate monohydrate phosphoric acid polysorbate 20 sodium hydroxide sucrose water for injection - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh of less than 1.2 iu/l.

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - follitropin alfa - injection, solution - 22.23 mcg - follitropin alfa 22.23 mcg

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - follitropin alfa - injection, solution - 33.34 mcg - follitropin alfa 33.34 mcg

European Union - English - EMA (European Medicines Agency)

n.v. organon - follitropin beta - infertility; hypogonadism - sex hormones and modulators of the genital system, - in the female:puregon is indicated for the treatment of female infertility in the following clinical situations:anovulation (including polycystic ovarian syndrome, pcos) in women who have been unresponsive to treatment with clomifene citrate;controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in-vitro fertilisation / embryo transfer (ivf/et), gamete intrafallopian transfer (gift) and intracytoplasmic sperm injection (icsi)).in the male:deficient spermatogenesis due to hypogonadotrophic hypogonadism.

European Union - English - EMA (European Medicines Agency)

merck europe b.v.  - follitropin alfa, lutropin alfa - infertility, female - sex hormones and modulators of the genital system, - pergoveris is indicated for the stimulation of follicular development in women with severe luteinising-hormone (lh) and follicle-stimulating-hormone deficiency.in clinical trials, these patients were defined by an endogenous serum lh level < 1.2 iu/l.

Israel - English - Ministry of Health

merck serono ltd - follitropin alfa; lutropin alfa - solution for injection - lutropin alfa 150 iu / 0.48 ml; follitropin alfa 300 iu / 0.48 ml - follitropin alfa - pergoveris is indicated for the stimulation of follicular development in adult women with sever lh and fsh deficiency.in clinical trials, these patients were defined by an endogenous serum lh level < 1.2iu/l

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sdn. bhd. - follitropin alfa; lutropin alfa -

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - follitropin beta 833 iu/ml;   - solution for injection - 833 iu/ml - active: follitropin beta 833 iu/ml   excipient: benzyl alcohol hydrochloric acid as 0.1n solution to adjust to ph 7.0 methionine polysorbate 20 sodium citrate dihydrate sodium hydroxide as 0.1n solution to adjust to ph 7.0 sucrose water for injection - in the female: - anovulatory infertility - controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programmes [e.g. in vitro fertilisation and related procedures].